OncoMatch/Clinical Trials/NCT07451652
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Is NCT07451652 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Gemcitabine (1000 mg/m2) for relapsed/refractory diffuse large b cell lymphoma.
Treatment: Epcoritamab · Gemcitabine (1000 mg/m2) · Oxaliplatin — In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: autologous stem cell transplant
Cannot have received: allogeneic stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07451652 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify